We have observed
2 EP applications
Lucy Clare Padget
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after May 28, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS
QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR